Lee Sheinkopf is a Rheumatology/Immunology physician affiliated with California Allergy and Asthma Medical Group. OpenAlex indexes 8 publications with 248 citations (h-index 3).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
11500 W Olympic Blvd Ste 630
Los Angeles, CA 900641538
Telephone
310-393-1550Provider last certified this registry record 11 Feb 2026.
Industry payments
38 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- AstraZeneca Pharmaceuticals LPProgram year202517 payments
- GENZYME CORPORATIONProgram year202513 payments
- GlaxoSmithKline, LLC.Program year202510 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Respiratory
99.3%Anti-IgE94.4%Omalizumab100%Part B, office-administered≥21 patientsCorticosteroid2.3%Breo Ellipta32%Trelegy Ellipta27%Symbicort19%Fluticasone Propionate13%Pulmicort Flexhaler9%Part D<11 patients+ 3 more classes in this area
Metabolism & gastrointestinal
0.4%Corticosteroid0.4%Prednisone100%Part D≥11 patientsDermatology
0.4%Interleukin-4 Receptor alpha Antagonist0.4%Dupixent Syringe100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Lengthening omalizumab dosing interval in treatment of moderate to severe persistent asthma
Journal of Allergy and Clinical Immunology
2019 - Clinical Control in the Dual Diagnosis of Obstructive Sleep Apnea Syndrome and Rhinitis: A Prospective Analysis
American Journal of Rhinology and Allergy
2014
Similar KOLs
Other experts from the same institution or the same specialty.
David J. Hunter
The University of Sydney
Aziz Sheikh
Universiti Malaysia Terengganu
Nima Hafezi‐Nejad
The University of Sydney
Gelin Xu
Second Affiliated Hospital of Nanjing Medical University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”